📑 Extensive Product Profile: Understanding Capnat 500mg Tablet

Capnat 500mg Tablet contains Capecitabine, an advanced, orally administered systemic prodrug of fluorouracil (an anti-metabolite fluoropyrimidine carbamate). Manufactured to rigorous international quality benchmarks, it is extensively deployed by global oncologists as a foundational component in monotherapy and combination chemotherapy regimens to manage mutation-specific and advanced malignancies.

1. Clinical Indications & Usage

Capnat 500mg is an oral targeted systemic chemotherapy globally indicated for:

• Colorectal Cancer:

• Adjuvant Colon Cancer: Indicated as a single agent for adjuvant treatment of patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor, when treatment with fluoropyrimidine therapy alone is preferred.

• Metastatic Colorectal Cancer: Deployed as first-line monotherapy or in combination frameworks for patients with metastatic colorectal carcinoma when staging warrants systemic intervention.

• Advanced or Metastatic Breast Cancer:

• Combination Therapy: Indicated in combination with docetaxel for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing cytotoxic chemotherapy.

• Monotherapy: Indicated as a single agent for the treatment of metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen.

• Gastric Cancer: Frequently utilized internationally in combination with platinum-based compounds for the frontline or maintenance treatment of advanced or metastatic gastric and gastroesophageal junction adenocarcinomas.

2. Mechanism of Action: How Capnat Works

Capnat utilizes a highly sophisticated, three-step enzymatic conversion pathway to target tumor cells while reducing systemic tissue exposure:

• Hepatic Metabolism to Prodrug Intermediates: Following oral absorption, Capecitabine passes through the liver intact, where it is converted by hepatic carboxylesterase to 5'-deoxy-5-fluorocytidine (5'-DFCR), which is then converted by cytidine deaminase into 5'-deoxy-5-fluorouridine (5'-DFUR).

• Tumor-Selective Activation: 5'-DFUR is converted to the active cytotoxic drug, 5-fluorouracil (5-FU), by the enzyme thymidine phosphorylase (TP). Crucially, levels of thymidine phosphorylase are significantly higher in distinct tumor tissues than in surrounding normal healthy tissues.

• Inhibition of DNA Synthesis (Synthetic Lethality): The active metabolite 5-FU further metabolizes into inhibitors that block thymidylate synthase, an enzyme critical for the synthesis of thymidine triphosphate. This disrupts DNA replication and compromises RNA processing, forcing the highly proliferative cancer cell into programmed cell death (apoptosis).

3. Administration and Dosing Guide

• Administration Route: Capnat 500mg is an oral tablet formulation. It must be swallowed whole with water within 30 minutes after completing a meal to optimize pharmacokinetic absorption. Tablets must never be crushed, chewed, split, or dissolved.

• Standard Schedule: The standard clinical starting dose is 1250 mg/m² administered orally twice daily (morning and evening; equivalent to a total daily dose of 2500 mg/m²) for a 2-week period, followed by a 1-week rest period given as 3-week cycles.

• Dose Titrations: Dose modifications, temporary interruptions, or percentage reductions (e.g., to 75% or 50% of the initial dose) are frequently managed by the treating oncologist based on individual hematological tolerance and renal clearance parameters.

⚠️ Safety, Side Effects, and Monitoring

Capnat 500mg is a highly potent cytostatic agent requiring strict clinical oversight:

• Diarrhea Management: Can cause severe, life-threatening diarrhea. Patients experiencing Grade 2 or higher diarrhea (an increase of 4 to 6 stools per day over baseline) must hold treatment immediately until symptoms resolve, under oncology direction.

• Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome): Characterized by numbness, tingling, burning pain, erythema, peeling, or blistering of the palms and soles. Early recognition requires immediate dose interruption or reduction.

• Cardiotoxicity: Myocardial infarction, angina, dysrhythmias, and ECG changes have been reported. Cardiotoxicity is more common in patients with a history of coronary artery disease.

• Hematological Toxicities: Neutropenia, anemia, and thrombocytopenia occur regularly. Baseline and baseline-interval Complete Blood Counts (CBC) along with hepatic and renal function tests are mandatory.

📦 Storage and Handling Specifications

• Storage Framework: Store Capnat 500mg tablets consistently below 25°C to 30°C (77°F to 86°F) in a dry, dark, climate-controlled warehouse corridor.

• Environmental Safeguards: Keep the tablets sealed tightly inside their original manufacturer packaging. Protect the blister cards from high humidity, excess moisture, and direct ambient UV light exposure. Keep strictly out of reach of children and domestic animals.

📄 Regulatory and Compliance Documentation

PRIMECARE IMPEX simplifies international border clearance and institutional sourcing workflows by providing a comprehensive, audit-ready document pack with every consignment:

• Authentic Certificate of Analysis (COA)

• Verified Batch Origin Ledger and commercial export documentation.

• GMP compliant manufacturing credentials.

💡 Why Choose PRIMECARE IMPEX?

Sourcing your institutional pharmaceuticals through PRIMECARE IMPEX guarantees a highly secure, verified supply chain setup:

• Full Traceability

• Regulatory Alignment

• Secure Bulk Supply

📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India

[GROUP OF PRIME CARE IMPEX PVT. LTD.]

Your Trusted Pharmaceutical Exporter, Bulk Supplier, and Global Distributor from India.

• 🌐 Corporate Website: www.medicineexporterfromindia.com

• 📧 Commercial Email: exports@ernestpharmaceuticals.com

• 📦 Business Type: Exporter | Bulk Supplier | Distributor

• 📲 Direct WhatsApp Line: +91 9673008130

• 🔗 Instant Chat Access: https://wa.me/919673008130